Trial Profile
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Brivanib alaninate (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours
- Focus Biomarker; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 12 Sep 2019 Results published in the European Journal of Cancer
- 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003668).
- 30 Apr 2012 Planned end date changed from 1 Feb 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.